Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 2

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

SILDENAFIL UPREGULATES TUMOR NECROSIS FACTOR α PRODUCTION IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF HEALTHY MEN - PRELIMINARY REPORT

100%
Kaleta B., Boguska A., Borysowski J., Górski A.
Acta Poloniae Pharmaceutica - Drug Research
|
2019
|
vol. 76
|
issue 1
123-128
EN
Sildenafil is a selective type 5 phosphodiesterase (PDE5) inhibitor, commonly used in the treatment of erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). The results of recent studies suggest that this drug modulates function of the immune system. However, only few studies were performed in humans. Therefore, the aim of this study was to investigate the ability of sildenafil to regulate the production of pro-inflammatory cytokines including tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β and IL-6 in peripheral blood mononuclear cells (PBMCs) from healthy men. Phorbol myristate acetate (PMA) - stimulated and unstimulated PBMCs from 16 participants were cultured in the absence or presence of sildenafil (400 ng/ml and 4 µg/ml). TNF-α, IL-1β and IL-6 concentrations in culture supernatants were measured by enzyme-linked immunosorbent assay (ELISA). Cell viability was assessed by trypan blue staining. Sildenafil at a concentration of 400 ng/ml significantly increased TNF-α production in stimulated PBMCs (p<0.05) but had no effects on IL-1β and IL-6. The drug did not affect PBMCs viability. This is the first report describing such effects of sildenafil in humans.
2
Publication available in full text mode
Content available

Interstitial pneumonia during treatment with rituximab

88%
Leś D., Polakiewicz-Gilowska A., Kaleta B., Starzyczny-Słota D., Nowara E.
OncoReview
|
2015
|
vol. 5
|
issue 1
A16-A20
EN
Rituximab (RTX) is a chimeric anti-CD20 antibody. It plays an important role in the treatment of B-cell lymphomas and diseases of autoaggression. RTX-induced lung disease is a rare entity, which should be considered in those patients treated with RTX who present with pulmonary disorders with no clear evidence of infection. A 37-year-old woman suffering from CD20-positive DLBCL (diffuse large B-cell lymphoma) received two cycles of the R-CHOP (RTX, cyclophosphamide, doxorubicin, vincristine and prednisone) regimen. After the second cycle of immunochemotherapy, symptoms of interstitial pneumonia occurred. Having excluded all the other causes, it was diagnosed as a complication associated with the administration of RTX.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.